GAAP net income was $296 million, or $1.99 per share,
compared to $209 million, or $1.41 per share, in the year-ago quarter. Adjusted
net income was $200 million, or $1.35 per share, ahead of forecasts of $1.34
per share.
Gross margin dipped to 68.4% from 69.3% last year. Adjusted
gross margin was 69.5% compared to 70.3% in the prior-year period. R&D
expenses rose 9% year-over-year to $166 million.
Francis deSouza, President and CEO
said, “In addition to continued sequencing consumables growth, we are
encouraged by the sequential and year-over-year growth in shipments across our
high, mid, and low-throughput sequencing system portfolio, including a record
number of NextSeq Dx systems, reflecting the growing clinical opportunity.”
During the quarter, Illumina launched Veriseq NIPT
v2, enabling a genome-wide screen which almost doubles the detection of
chromosomal abnormalities. The company also partnered with AnchorDx, a
molecular diagnostics company, to develop clinical oncology products for the
Chinese market.
For the full year of 2019, Illumina expects revenues to grow approx. 6%. GAAP EPS is expected to be $6.41 to $6.51 and adjusted EPS is estimated to be $6.00 to $6.10.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.